Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 2
1989 4
1990 2
1991 1
1993 3
1994 4
1995 2
1996 3
1997 6
1998 11
1999 10
2000 26
2001 20
2002 24
2003 25
2004 26
2005 31
2006 45
2007 30
2008 36
2009 30
2010 39
2011 34
2012 48
2013 42
2014 47
2015 23
2016 25
2017 28
2018 40
2019 32
2020 50
2021 60
2022 65
2023 40
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

822 results

Results by year

Filters applied: . Clear all
Page 1
Evidence and Choice: The BCLC Vision for Tailoring Clinical Decision-Making.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. Reig M, et al. Among authors: galle pr. J Hepatol. 2024 May 8:S0168-8278(24)00321-0. doi: 10.1016/j.jhep.2024.04.023. Online ahead of print. J Hepatol. 2024. PMID: 38729354 No abstract available.
PHES scores have limited impact on the risk of overt HE in patients with minimal HE.
Gairing SJ, Mangini C, Zarantonello L, Jonasson E, Danneberg S, Sultanik P, Galle PR, Gioia S, Labenz J, Lok AS, Marquardt JU, Lauridsen MM, Bloom PP, Thabut D, Nardelli S, Montagnese S, Labenz C. Gairing SJ, et al. Among authors: galle pr. Hepatol Commun. 2024 May 3;8(5):e0438. doi: 10.1097/HC9.0000000000000438. eCollection 2024 May 1. Hepatol Commun. 2024. PMID: 38701395 Free PMC article.
Lower uromodulin serum levels are associated with poorer prognosis in patients with cirrhosis and hepatorenal syndrome type 2.
Schleicher EM, Gairing SJ, Castven D, Hock CS, Dobbermann H, Heinrich S, Meineck M, Kaps L, Galle PR, Weinmann-Menke J, Nguyen-Tat M, Marquardt JU, Labenz C. Schleicher EM, et al. Among authors: galle pr. Am J Physiol Gastrointest Liver Physiol. 2024 May 1;326(5):G583-G590. doi: 10.1152/ajpgi.00304.2023. Epub 2024 Mar 19. Am J Physiol Gastrointest Liver Physiol. 2024. PMID: 38502914
Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study.
Armandi A, Bespaljko H, Mang A, Huber Y, Michel M, Labenz C, Galle PR, Neerukonda M, Bugianesi E, Schuppan D, Schattenberg JM. Armandi A, et al. Among authors: galle pr. Aliment Pharmacol Ther. 2024 May;59(10):1212-1222. doi: 10.1111/apt.17941. Epub 2024 Mar 11. Aliment Pharmacol Ther. 2024. PMID: 38462919 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Among authors: galle pr. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018.
Pantke A, Kollan C, Gunsenheimer-Bartmeyer B, Jensen BO, Stephan C, Degen O, Schürmann D, Kurth T, Bremer V, Koppe U; HIV-1 Seroconverter Cohort and the ClinSurv HIV Cohort. Pantke A, et al. Infection. 2024 Apr;52(2):637-648. doi: 10.1007/s15010-024-02188-y. Epub 2024 Feb 21. Infection. 2024. PMID: 38381307 Free PMC article.
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
Balcar L, Scheiner B, Fulgenzi CAM, D'Alessio A, Pomej K, Roig MB, Meyer EL, Che J, Nishida N, Lee PC, Wu L, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal YI, Chamseddine S, Wietharn B, Parisi A, Huang YH, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle PR, Stauber R, Kudo M, Singal AG, Itani A, Ulahannan SV, Parikh ND, Cortellini A, Kaseb A, Rimassa L, Chon HJ, Pinato DJ, Pinter M. Balcar L, et al. Among authors: galle pr. JHEP Rep. 2023 Dec 12;6(2):100982. doi: 10.1016/j.jhepr.2023.100982. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38274490 Free PMC article.
N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas.
Gerber TS, Ridder DA, Goeppert B, Brobeil A, Stenzel P, Zimmer S, Jäkel J, Metzig MO, Schwab R, Martin SZ, Kiss A, Bergmann F, Schirmacher P, Galle PR, Lang H, Roth W, Straub BK. Gerber TS, et al. Among authors: galle pr. Int J Cancer. 2024 May 15;154(10):1857-1868. doi: 10.1002/ijc.34836. Epub 2024 Jan 11. Int J Cancer. 2024. PMID: 38212892 Free article.
Leitlinienreport der S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome“.
Groß S, Bitzer M, Blödt S, Fischer N, Follmann M, Freudenberger P, Langer T, Lynen Jansen P, Nothacker M, Steubesand N, Galle PR, Malek NP. Groß S, et al. Among authors: galle pr. Z Gastroenterol. 2024 Jan;62(1):e162-e212. doi: 10.1055/a-2189-6197. Epub 2024 Jan 9. Z Gastroenterol. 2024. PMID: 38195104 Free article. German. No abstract available.
822 results